News >

Lenvatinib Extends PFS in Differentiated Thyroid Cancer

Christina Izzo
Published: Monday, Feb 03, 2014

Papillary Carcinoma of the Thyroid

Scrape cytology illustrating features of papillary carcinoma of the thyroid.

The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication